Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Spatial biomarkers of CAR-T treatment response in relapsed refractory multiple myeloma

Julia Wang, Chenchen Peng, Reyka Jayasinghe, Michael Slade, Xiangwei Fang, Julie Fortier, Mark Fiala, Yuxuan Pan, Preet Lal, Yuting Zhao, Kiran Vij, Chaitanya Acharya, George Mulligan, John DiPersio, Feng Chen, Ravi Vij, Li Ding

Blood (2025) 146 (Supplement 1): 5804.

https://doi.org/10.1182/blood-2025-5804

Published: 2025

Journal Articles

primary analysis of Phase ib trial of duvelisib for cytokine release syndrome prophylaxis in patients undergoing chimeric antigen receptor T cell therapy for non-hodgkins lymphoma

Michael Slade, Michael Rettig, Parmeshwar Amatya, Zachary Crees, Brad Kahl, Neha Mehta-Shah, Dilan Patel, David Russler-Germain, Nancy Bartlett, Amanda Cashen, Iskra Pusic, Geoffrey Uy, John DiPersio, Armin Ghobadi

Blood (2025) 146 (Supplement 1): 929.

https://doi.org/10.1182/blood-2025-929

Published: 2025

Journal Articles

Motixafortide + G-CSF hematopoietic stem cell mobilization in patients with multiple myeloma following quadruplet induction therapy

Zachary Crees, Mark Schroeder, Michael Slade, Keith Stockerl-Goldstein, Ravi Vij, Ella Sorani, Irit Glicko-Kabir, Michael Rettig, John DiPersio

Blood (2025) 146 (Supplement 1): 5957.

https://doi.org/10.1182/blood-2025-5957

Published: 2025

Journal Articles

Pilot study of cell-free DNA (cfDNA) for measurable residual disease monitoring following autologous hematopoietic cell transplant in multiple myeloma

Yamuna Kondapally, Julie Fortier, Antony Tin, Sarah Kelley, Derrick Renner, Mark Fiala, Angel Rodriguez, Minetta Liu, Mark Schroeder, Keith Stockerl-Goldstein, Ravi Vij, Michael Slade

Blood (2025) 146 (Supplement 1): 2219.

https://doi.org/10.1182/blood-2025-2219

Published: 2025

Journal Articles

Feasibility of risk classification with newly proposed international myeloma working group (IMWG) high-risk definition: A single-center analysis using natural language processing

Michael Slade, Mark Fiala, Julie Fortier, Sarah Kelley, David Spencer, Mark Schroeder, Keith Stockerl-Goldstein, Ravi Vij

Blood (2025) 146 (Supplement 1): 2218.

https://doi.org/10.1182/blood-2025-2218

Published: 2025

Journal Articles

Kinetics of circulating multiple myeloma cells (CMMCs) in patients undergoing standard-of-care anti-BCMA chimeric antigen receptor T cell therapy for Relapsed/Refractory multiple myeloma

Michael Slade, Julie Fortier, Mark Fiala, Binod Dhakal, Hans Lee, Frank Kuhr, Wojciech Swat, Paola Tononi, Nicolo Manaresi, Alberto Ferrarini, Sarah Kelley, Mark Schroeder, Keith Stockerl-Goldstein, Ravi Vij

Blood (2025) 146 (Supplement 1): 5851.

https://doi.org/10.1182/blood-2025-5851

Published: 2025

Journal Articles

Experiences of patients with multiple myeloma enrolled in high-deductible health plans: A mixed-methods study

Matthew Kaczynski, Akshay Mehta, Atman Shah, Enoch Park, Shelbie Fishman, Michael Slade, Ravi Vij, Mark Fiala

Blood (2025) 146 (Supplement 1): 4413.

https://doi.org/10.1182/blood-2025-4413

Published: 2025

Journal Articles

Cellular senescence associated with aging and chemotherapy exposure primes bone marrow for immune dysfunction and myeloma persistence

Blood (2025) 146 (Supplement 1): 4955.

https://doi.org/10.1182/blood-2025-4955

Published: 2025

Journal Articles

Spatially resolved transcriptomics reveals immunosuppressive niches and clonal diversity in extramedullary disease in multiple myeloma refractory to immunotherapy

Blood (2025) 146 (Supplement 1): 3949.

https://doi.org/10.1182/blood-2025-3949

Published: 2025

Journal Articles

Shared immune features correspond to high-risk multiple myeloma across multiple human subtypes and murine models

Blood (2025) 146 (Supplement 1): 5723.

https://doi.org/10.1182/blood-2025-5723

Published: 2025

Journal Articles

Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 4012.

https://doi.org/10.1182/blood-2025-4012

Published: 2025

Journal Articles

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Blood (2024) 144 (Supplement 1): 4654.

https://doi.org/10.1182/blood-2024-208308

Published: 2024

Journal Articles

Convenience Versus Continuity: A Natural History Study of a Newly Opened Plasma Cell Disorders Clinic in an Underserved Community and Desire for Transfer of Care Among Previously Diagnosed Patients

Michael Slade, Ravi Vij, Keith Stockerl-Goldstein, Mark A. Schroeder, Angela Vickroy, Margaret Kavanaugh, Carmen Wilson, Mark Fiala

Blood (2024) 144 (Supplement 1): 3653.

https://doi.org/10.1182/blood-2024-203469

Published: 2024

Journal Articles

Impact of Absolute Lymphocyte Counts (ALC) on Outcomes Following Bispecific Antibody Therapy in Patients with Relapsed/Refractory Multiple Myeloma Patients: A Single Center Real-World Experience

Yash Shah, Mark Fiala, Keith Stockerl-Goldstein, Mark A. Schroeder, Ravi Vij, Zachary D. Crees, Michael Slade

Blood (2024) 144 (Supplement 1): 3792.1.

https://doi.org/10.1182/blood-2024-209293

Published: 2024

Journal Articles

Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4687.

https://doi.org/10.1182/blood-2024-209181

Published: 2024

Journal Articles

Evaluating Diagnostic Performance of Light Chain Dimerization By Mass Spectrometry to Distinguish between AL Amyloidosis and Monoclonal Gammopathy of Undetermined Significance

Alexa Loncharich, Mark Fiala, Julie Fortier, Keith Stockerl-Goldstein, Ravi Vij, Mark A. Schroeder, Mark Zaydman, Michael Slade, Mariya Liyasova

Blood (2024) 144 (Supplement 1): 1921.

https://doi.org/10.1182/blood-2024-211395

Published: 2024

Journal Articles

A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Sueh-Li Lim, Bradley Augustson, Hira S Mian, Edward A. Stadtmauer, Shinsuke Iida, Michael Slade, Saswati Hazra, Kamal Chamoun, Patricia Cheung, Jamal Saeh, Nina Shah, Amrita Y Krishnan

Blood (2024) 144 (Supplement 1): 2000.2.

https://doi.org/10.1182/blood-2024-207816

Published: 2024

Journal Articles

Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Blood (2024) 144 (Supplement 1): 224.

https://doi.org/10.1182/blood-2024-201694

Published: 2024

Journal Articles

Real-World Experience with Elotuzumab, Pomalidomide, and Dexamethasone As Second or Third-Line Therapy in Relapsed and Refractory Multiple Myeloma

Akhil Kesaraju, Alexa Loncharich, Keith Stockerl-Goldstein, Mark A. Schroeder, Angela Vickroy, Ravi Vij, Michael Slade

Blood (2024) 144 (Supplement 1): 6936.

https://doi.org/10.1182/blood-2024-208241

Published: 2024

Journal Articles

Patient Recorded Outcomes from a Randomized, Controlled Phase 2 Trial of E-Selectin Inhibition with Uproleselan Vs Placebo to Reduce GI Toxicity during Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Meaghan Ryan, Zachary David Crees, Michael Slade, Mark A. Schroeder, Ravi Vij, Geoffrey L Uy, Keith Stockerl-Goldstein

Blood (2023) 142 (Supplement 1): 2217.

https://doi.org/10.1182/blood-2023-179604

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Spatial biomarkers of CAR-T treatment response in relapsed refractory multiple myeloma

primary analysis of Phase ib trial of duvelisib for cytokine release syndrome prophylaxis in patients undergoing chimeric antigen receptor T cell therapy for non-hodgkins lymphoma

Motixafortide + G-CSF hematopoietic stem cell mobilization in patients with multiple myeloma following quadruplet induction therapy

Pilot study of cell-free DNA (cfDNA) for measurable residual disease monitoring following autologous hematopoietic cell transplant in multiple myeloma

Feasibility of risk classification with newly proposed international myeloma working group (IMWG) high-risk definition: A single-center analysis using natural language processing

Kinetics of circulating multiple myeloma cells (CMMCs) in patients undergoing standard-of-care anti-BCMA chimeric antigen receptor T cell therapy for Relapsed/Refractory multiple myeloma

Experiences of patients with multiple myeloma enrolled in high-deductible health plans: A mixed-methods study

Cellular senescence associated with aging and chemotherapy exposure primes bone marrow for immune dysfunction and myeloma persistence

Spatially resolved transcriptomics reveals immunosuppressive niches and clonal diversity in extramedullary disease in multiple myeloma refractory to immunotherapy

Shared immune features correspond to high-risk multiple myeloma across multiple human subtypes and murine models

Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM)

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Convenience Versus Continuity: A Natural History Study of a Newly Opened Plasma Cell Disorders Clinic in an Underserved Community and Desire for Transfer of Care Among Previously Diagnosed Patients

Impact of Absolute Lymphocyte Counts (ALC) on Outcomes Following Bispecific Antibody Therapy in Patients with Relapsed/Refractory Multiple Myeloma Patients: A Single Center Real-World Experience

Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Evaluating Diagnostic Performance of Light Chain Dimerization By Mass Spectrometry to Distinguish between AL Amyloidosis and Monoclonal Gammopathy of Undetermined Significance

A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Real-World Experience with Elotuzumab, Pomalidomide, and Dexamethasone As Second or Third-Line Therapy in Relapsed and Refractory Multiple Myeloma

Patient Recorded Outcomes from a Randomized, Controlled Phase 2 Trial of E-Selectin Inhibition with Uproleselan Vs Placebo to Reduce GI Toxicity during Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only